Prospective comparison of Luseogliflozin and alpha-glucosidase inhibitor on the management of diabetic patients with chronic heart failure and preserved left-ventricular ejection fraction

Conditions

heart failure

Kentaro Ejiri, Toru Miyoshi, Hajime Kihara, Yoshiki Hata, Toshihiko Nagano et al. (44 authors)

Scientific Reports2022-09-1423 citations

10.1038/s41598-022-19371-6

Effects of Luseogliflozin on Estimated Plasma Volume in Patients with Heart Failure with Preserved Ejection Fraction

M Nakashima, Toru Miyoshi, Kentaro Ejiri, Hajime Kihara, Yoshiki Hata et al. (20 authors)

ESC Heart Failure2021-11-0310 citations

10.1002/ehf2.13683

Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.

Ejiri K, Miyoshi T, Kihara H, Hata Y, Nagano T, Takaishi A, Toda H, Nanba S, Nakamura Y, Akagi S, Sakuragi S, Minagawa T, Kawai Y, Nishii N, Fuke S, Yoshikawa M, Nakamura K, Ito H, MUSCAT‐HF Study Investigators †.

2020-08-0138 citations

10.1161/jaha.119.015103

The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial

Kentaro Ejiri, Toru Miyoshi, Kazufumi Nakamura, Satoru Sakuragi, Mitsuru Munemasa et al. (8 authors)

BMJ Open2019-03-0112 citations

10.1136/bmjopen-2018-026590

Interventions

SGLT2 inhibitor, luseogliflozin 5 mg once a day alpha-glucosidase inhibitor, voglibose 0.3mg three times/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Type 2 diabetic patients with LV ejection fraction > 45% and a symptom of heart failure 2) Inadequately controlled type 2 diabetic patients who have received alimentary therapy, exercise therapy, a lifestyle modification program, and hypoglycemic medications 3) Age >40 years and <75 years 4) Patients from whom a written informed consent was obtained

Exclusion criteria

Exclusion criteria: 1) BNP <35 pg/ml 2) Patients receiving alpha-glucosidase inhibitors, SGLT2 inhibitors, glinides, high-dose sulfonylurea 3) Patients with renal insufficiency (eGFR< 30 ml/min/1.73m2) 4) LVEF<45% 5) Patients with history of severe ketoacidosis, diabetic coma within six months 6) Patients with serious infection and severe trauma, and perioperative patients 7) Type 1 diabetes mellitus 8) Poorly controlled type2 diabetic patients (HbA1c > 9.0%) 9) Uncontrolled hypertensive patients (systolic blood pressure >160mmHg) 10) Patients with history of stroke, myocardial infarction and severe cardiovascular disease with hospitalization within six months 11) Pregnant women and breast-feeding women 12) Patients with allergy for test drugs 13) Patients who is not suitable to this study due to medical reasons

Design outcomes

Primary

Measure	Time frame
Change in BNP at 12 weeks	—

Countries

Japan

Contacts

Public ContactToru Miyoshi

Okayama University Graduate School of. Medicine, Dentistry and Pharmaceutical Sciences Cardiovascular Medicine

miyoshit@cc.okayama-u.ac.jp086-235-7351

Outcome results

None listed